論文・技術情報追加のお知らせ

1. A replication study using the World Health Organization pharmacovigilance database (VigiBase(R)) to evaluate whether an association between ketamine and esketamine and alcohol and substance misuse exists.

ケタミンは薬物乱用リスクが高いが、エスケタミンではそのリスクが低い

対象DB：FAERS,VigiBase

2. Comprehensive analysis of adverse events associated with pimavanserin using the FAERS database.

ピマバンセリンの副作用に関する分析で、睡眠障害や認知変化が確認

対象DB：FAERS

3. Safety of TNF-alpha inhibitors: A real-world study based on the US FDA Adverse Event Reporting System Database.

TNFα阻害薬の副作用を分析し、特定薬剤に注意喚起

対象DB：FAERS

4. Adverse events associated with eteplirsen: A disproportionality analysis using the 2016-2023 FAERS data.

エテプリルセンの副作用をFAERSで分析、新たな安全性問題を発見

対象DB：FAERS

5. A disproportionality analysis of adverse events caused by GnRHas from the FAERS and JADER databases.

GnRHaの副作用をFAERSとJADERで分析、新たなシグナルを発見

対象DB：FAERS,JADER

6. Safety assessment of dapagliflozin: Real-world adverse event analysis based on the FAERS database from 2012 to 2023.

ダパグリフロジンの副作用分析、特に急性膵炎など新たなリスク

対象DB：FAERS

7. Assessment of adverse events of the novel cardiovascular drug vericiguat: a real-world pharmacovigilance study based on FAERS.

ベリシグアットの副作用分析、主に低血圧とめまい

対象DB：FAERS

8. Comparing musculoskeletal and connective tissue disorder risks of teriparatide and abaloparatide in osteoporosis: an analysis based on FDA adverse event reporting system (FAERS).

テリパラチドとアバロパラチドの筋骨格系副作用をFAERSで分析

対象DB：FAERS

9. Clinical adverse events to dexmedetomidine: a real-world drug safety study based on the FAERS database.

デクスメデトミジンの副作用をFAERSで分析

対象DB：FAERS

10. Infection associated with CDK4/6 inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system database.

CDK4/6阻害剤の感染関連副作用をFAERSで分析

対象DB：FAERS

11. Hemorrhagic events associated with tacrolimus: a real-world pharmacovigilance study.

タクロリムスの出血副作用をFAERSで分析

対象DB：FAERS

12. Adverse drug events associated with fluorouracil use in patients with metastatic colorectal cancer: a real-world pharmacovigilance study based on the FDA adverse event reporting system.

5-FUの副作用は主に消化器系で、男性は体重減少や皮膚毒性に敏感

対象DB：FAERS

13. Spectrum of psychiatric adverse reactions to cyclin-dependent kinases 4/6 inhibitors: A pharmacovigilance analysis of the FDA adverse event reporting system.

CDK4/6阻害薬は精神的副作用のリスクがあり、特にリボシクリブが高い

対象DB：FAERS

14. Adverse Events of COVID-19 Vaccines in the United States: Temporal and Spatial Analysis.

COVID-19ワクチンの副作用は時間と地域による傾向

対象DB：FAERS,VAERS

15. Hypercalcemia in children induced by denosumab: a case report and an analysis of the FDA adverse event reporting system database.

デノスマブ中止後の小児での高カルシウム血症のリスクが高く、特に男性や若年層に注意が必要

対象DB：FAERS

16. Data mining study on adverse events of tirzepatide based on FAERS database.

ティルゼパチドの副作用には新たなシグナルがあり、初期の慎重な監視が必要

対象DB：FAERS

17. Cardiac adverse events associated with lacosamide: a disproportionality analysis of the FAERS database.

ラコサミドの心臓関連副作用のリスクは低下傾向にある

対象DB：FAERS

18. Validation of the newly proposed Brighton Collaboration case definition for vaccine-induced immune thrombocytopenia and thrombosis.

VITTのケース定義は高い診断精度を示した

対象DB：FAERS,VAERS

19. Cross-Cancer Type Evaluation of Potential Interstitial Lung Disease Complications of Immune Checkpoint Inhibitors Using JADER.

免疫チェックポイント阻害剤は癌種により間質性肺疾患リスクが異なる

対象DB：JADER

20. Association Between the Dose of Tofacitinib and Risk of Herpes Zoster in Patients With Rheumatoid Arthritis: Analysis of Japanese Adverse Drug Event Report Data.

トファシチニブ5mgは10mgより帯状疱疹リスクが低い可能性がある

対象DB：JADER

21. Safety of fingolimod in patients with relapsing remitting multiple sclerosis: A descriptive analysis of data from the EudraVigilance database.

フィンゴリモドの安全性評価では長期的な薬剤監視が重要

対象DB：EudraVigilance

22. Overview of global monitoring systems for the side effects and adverse events associated with medicinal cannabis use: a scoping review using a systematic approach.

医療用大麻の副作用監視には一貫したシステムが必要

対象DB：VigiBase

23. Characterization of second primary malignancies post CAR T-cell therapy: real-world insights from the two global pharmacovigilance databases of FAERS and VigiBase.

CAR-T治療後の二次がんリスク増加が確認された

対象DB：VigiBase

24. Cardiovascular and cerebrovascular adverse events associated with intravitreal anti-vascular endothelial growth factor monoclonal antibodies: a World Health Organization pharmacovigilance study.

抗VEGF治療後の心血管・脳血管副作用増加が確認された

対象DB：VigiBase

25. Normal saline versus Ringer's solution and critical-illness mortality in acute pancreatitis: a nationwide inpatient database study.

急性膵炎治療にはリンガー液が生理食塩水より有効

対象DB：DPC

26. Development and validation of an automated antimicrobial surveillance system based on indications for antimicrobial administration.

APBSSは抗菌薬使用と主な市中感染症を高精度で識別可能

対象DB：DPC

27. Association between benzodiazepine anxiolytic polypharmacy and concomitant psychotropic medications in Japan: a retrospective cross-sectional study.

併用抗うつ薬・抗精神病薬はベンゾジアゼピン多剤処方と関連

対象DB：JMDC

28. Overcoming Time-Varying Confounding in Self-Controlled Case Series with Active Comparators: Application and Recommendations.

時間変動する交絡因子に対応するための新手法の紹介

対象DB：CPRD

29. Can metformin prevent cancer relative to sulfonylureas? A target trial emulation accounting for competing risks and poor overlap via double/debiased machine learning estimators.

メトホルミンは癌予防効果がなく、有意差が確認できず

対象DB：CPRD

30. External validation of a prognostic model to improve prediction of psychosis in primary care.

リスク予測ツールP Riskは早期精神病リスクを検出し、初期診断を支援する

対象DB：CPRD

31. Longitudinal trajectories of frailty are associated with short-term mortality in older people: a joint latent class models analysis using 2 UK primary care databases.

高齢者の虚弱進行の軌跡と死亡リスクを特定し、迅速な進行群を重点的に監視する必要がある

対象DB：CPRD